Interface Consultation Services, PLLC

Miki Peer, Claudio N. Soares, MD, PhD, and Meir Steiner, MD, PhD Ms Peer reports that she has no conflicts of interest concerning the subject matter of this article. Dr Soares reports that he has received grant/research support from AstraZeneca and GlaxoSmithKline; he is a consultant for Sepracor, GlaxoSmithKline, Wyeth-Ayerst, and Neurocrine; and he is on the Promotional Speakers' Bureau of GlaxoSmithKline, Wyeth-Ayerst, Forest Laboratories, and Pfizer. Dr Steiner reports that he has received grant/ research support from Wyeth, Pfizer, and AstraZeneca; he is a consultant for Eli Lilly, Pfizer, GlaxoSmithKline, Lundbeck, Novartis, Wyeth, OrthoMcNeil, AstraZeneca, and Azevan Pharmaceuticals; he is on the advisory board of Eli Lilly, GlaxoSmithKline, Pfizer, Lundbeck, OrthoMcNeil, Wyeth, Schering, Ferring, and Azevan Pharmaceuticals; and he is on the Speakers' Bureau of AstraZeneca, GlaxoSmithKline, Eli Lilly, and Wyeth. The ocurrence and severity of anxiety disorders have been c

Provided by: Associated PressWritten by: THE ASSOCIATED PRESS Sep. 17, 2008 CHICAGO - A government agency in the United States has dropped plans to test a controversial treatment for autism that critics had called an unethical experiment on children. The National Institute of Mental Health said in a statement Wednesday that the study of chelation (kee-LAY'-shun) has been discontinued. The statement says the agency decided the money would be better used testing other potential therapies for autism and related disorders. The study had been on hold because of safety concerns . A study published last year linked a chemical used in the treatment to lasting brain problems in rats. The treatment removes heavy metals from the body and is based on the fringe theory that mercury in vaccines triggers autism - a theory never proved and rejected by mainstream science.